Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Merck Sharp & Dohme LLC
Nurix Therapeutics, Inc.
AbbVie
Rigshospitalet, Denmark
Beth Israel Deaconess Medical Center
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
University of Chicago
Gilead Sciences
University of Washington
Mayo Clinic
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
Dana-Farber Cancer Institute
Ascentage Pharma Group Inc.
Mayo Clinic
Newave Pharmaceutical Inc
Schrödinger, Inc.
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
BeOne Medicines
Eli Lilly and Company
AbbVie
BeOne Medicines